Hypercholesterolemia in bulimia nervosa

Serum Lipid Levels in Patients with Eating Disorders

Objective To evaluate some risk factors for cardiovascular diseases in feeding and eating disorders, the degree of lipid abnormalities was investigated in a large Japanese cohort of different groups of feeding and eating disorders, according to the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012 (JAS Guidelines 2012). Methods Participants in the current study included 732 women divided into four groups of feeding and eating disorders: anorexia nervosa, restricting type (AN-R); anorexia nervosa, binge-eating/purging type; bulimia nervosa (BN); and binge-eating disorder (BED). We measured the serum levels of total cholesterol, high-density-lipoprotein (HDL) cholesterol, and triglyceride in these participants. Low-density-lipoprotein (LDL) cholesterol and non-HDL cholesterol levels were also calculated. Results The concentrations of LDL cholesterol and non-HDL cholesterol were widely distributed in all groups. When the LDL cholesterol risk was defined as ≥120 mg/dL and the non-HDL cholesterol risk as ≥150 mg/dL, according to the JAS Guidelines 2012, the proportion of LDL cholesterol risk ranged from 29.6% (BN) to 38.6% (AN-R), and the proportion of non-HDL cholesterol risk ranged from 17.8% (BN) to 30.1% (BED). Conclusion The present findings suggest the existence of LDL cholesterol risk and non-HDL cholesterol risk in all groups of eating disorders. Given the chronicity of this condition, the development of elevated concentrations of LDL cholesterol and non-HDL cholesterol at an early age may increase the risk of cardiovascular diseases.

Enhanced serum cholesterol and triglyceride levels in bulimia nervosa: relationships to psychiatric comorbidity, psychopathology and hormonal variables

Increased levels of cholesterol have been reported in patients with bulimia nervosa (BN), but all but one of the published studies were performed on non-fasting subjects, which limits the interpretation of this finding. Moreover, the relationships between serum lipids and comorbid psychiatric disorders or bulimic psychopathology have scarcely been investigated. We measured serum levels of total cholesterol, triglycerides, glucose, 17beta-estradiol and thyroid hormones in 75 bulimic women and 64 age-matched healthy females after an overnight fast. Compared with healthy women, bulimic patients exhibited significantly enhanced serum levels of cholesterol and triglycerides, but similar values of glucose, 17beta-estradiol, FT3 and FT4. No significant differences emerged in these variables between patients with or without comorbid depression, borderline personality disorder or lifetime anorexia nervosa. Circulating cholesterol was positively correlated to the patients' drive for thinness, ineffectiveness, enteroceptive awareness and impulse regulation sub-item scores of the Eating Disorder Inventory-2. These findings confirm that BN is associated with increased levels of serum lipids. This alteration may be involved in the pathophysiology of certain psychopathological characteristics of BN and cannot be explained by the co-occurrence of other psychiatric disorders.

Opposite changes in circulating adiponectin in women with bulimia nervosa or binge eating disorder

Adiponectin is a recently discovered peripheral peptide that is secreted exclusively by differentiated adipocytes. It has been shown to enhance insulin sensitivity, control body weight, regulate lipid homeostasis, and prevent atherosclerosis. Dysregulation of both lipid and glucose metabolism and changes in body weight and body fat mass have been reported in bulimia nervosa (BN) and/or binge eating disorder (BED); hence, investigation of adiponectin secretion is of obvious interest in these eating disorders. To this purpose, we measured plasma levels of adiponectin, glucose, cholesterol, triglycerides, and thyroid hormones in 60 drug-free women, including 20 patients with BN, 20 patients with BED, and 20 healthy controls. Compared with healthy women, BN women exhibited significantly increased circulating adiponectin levels (P < 0.002) and cholesterol concentrations (P < 0.005), whereas BED women had significantly reduced plasma levels of adiponectin (P < 0.005) and increased concentrations of glucose (P < 0.01), cholesterol (P < 0.05), and triglycerides (P < 0.02). Moreover, plasma levels of adiponectin were significantly correlated to the frequency of binge/vomiting episodes (r = 0.65, P = 0.002) in bulimics but not to the frequency of bingeing in BED patients. Because we did not include a group of obese patients who did not binge eat, the specificity of our findings in the BED should be considered cautiously. However, on the basis of present results, it is tempting to speculate that the increased production of adiponectin in BN may represent a compensatory mechanism to counteract the possible development of insulin resistance, whereas the decreased secretion of adiponectin in individuals with BED may be a risk factor for the development of glucose intolerance.

The effect of bulimia nervosa on plasma glucose and lipids

This analysis examined changes in plasma lipids and glucose after 3 years in women treated for bulimia nervosa (BN). One hundred and thirty-five women aged 17-45 years with DSM-III-R BN entered a 12-week cognitive behavioral therapy treatment programme. Prior to and 3 years after treatment, patients completed psychiatric and behavioral assessments and fasting blood samples were drawn. At 3-year follow-up, 105 women were available, 67.6% of whom had no eating disorder and 32.4% of whom had any eating disorder (16.2% with eating disorder not otherwise specified and 16.2% with BN). Women with no eating disorder diagnosis at 3-year follow-up experienced a significant mean decrease in plasma glucose from pretreatment to 3-year follow-up compared to those with any eating disorder diagnosis. Eating disorder diagnosis at 3-year follow-up was independently associated with change in plasma glucose when potential confounders were adjusted for. Plasma triglyceride concentrations did not change in the group as a whole. Plasma HDL-cholesterol increased and total cholesterol decreased significantly from pretreatment to 3-year follow-up in the group as a whole. The decrease in serum cholesterol was significant in women with no eating disorder, but not in the women with any eating disorder diagnosis at 3-year follow-up. We conclude that a protracted course of BN may result in clinically insignificant increases in glucose concentrations and may attenuate the decrease in total cholesterol that is observed in women who recover from BN.

Serum cholesterol in bulimia nervosa

OBJECTIVE

The purpose of this retrospective study was to replicate and to extend previous work indicating that bulimia nervosa is associated with elevated serum levels of cholesterol and to examine the association between cholesterol and other clinical and serum measures.

METHODS

Clinical characteristics and laboratory data including nonfasting cholesterol and thyroid indices were collected from charts of 119 women with bulimia nervosa and 42 female controls.

RESULTS

There was no significant difference between the two groups in mean age or body mass index. The mean serum cholesterol level of the patient group was statistically significantly greater than that of the control group (patients: 194 +/- 36 mg/dl; controls: 176 +/- 34 mg/dl; t = 2.77; df = 159; p =.006). The mean calculated free T4 of the bulimia nervosa patient group was statistically lower than that of the control group (patients: 1.89 +/- 0.32; controls: 2.09 +/- 0.26; t = 2.86; df = 141; p =.005). There was no correlation between calculated free T4 and serum cholesterol within the combined group (r =.04, p >.5, N = 143) or within the patient group (r =.08, p >.3, N = 118).

CONCLUSIONS

The average serum level of cholesterol is elevated in the patients with bulimia nervosa. The mechanism for and the consequences of this abnormality are uncertain.

Elevated plasma lipids in patients with binge eating disorders are found only in those who are anorexic

OBJECTIVE

We have previously shown that patients with restricting type anorexia nervosa (AN-R) have low plasma lipid levels, which increase with refeeding. In this study, we investigated plasma lipid levels in patients with eating disorders, distinguishing between individuals with bulimia nervosa (BN) and anorexia nervosa of the binge eating/purging type (AN-B).

METHODS

We examined the fasting lipid levels in individuals with BN (n = 10) and AN-B (n = 9), and compared these findings with a group of age-matched normal weight healthy controls (C) (n = 10).

RESULTS

The AN-B group had significantly higher concentrations of total plasma cholesterol, apolipoprotein (apo) B, apoA1, and low-density lipoprotein (LDL)-cholesterol than both control and BN groups (p < .05). The AN-B group also had higher plasma triglycerides and intermediate-density lipoprotein (IDL)-apo B levels (p < .05) than controls.

DISCUSSION

In conclusion, the issue of hyperlipidemia in patients with eating disorders is a complex one and this study, taken together with the findings of our previous study, demonstrates the importance of carefully distinguishing between the major types of eating disorders (AN-R, BN, and AN-B) when examining plasma lipid levels.

Nutritional management of eating disorders

Abnormal nutritional status and dietary patterns are central features of the eating disorders. Normalization of these features are key components of treatment and recovery because they are powerful perpetuating factors. Restrictive diets, fat avoidance, and abnormal cognitive and perceptual patterns are typically present, in addition to altered nutritional parameters because of hormonal and metabolic factors. The primary goal of nutrition intervention in the patient with anorexia nervosa is to promote weight gain through increased energy intake, expansion of the diet, and knowledgeable and empathetic dietary counseling. A regular pattern of nutritionally balanced, planned meals and snacks, and the avoidance of restrictive dieting, are essential elements of treatment for the patient with bulimia nervosa. As a member of the multidisciplinary treatment team, the dietitian or nutrition professional with knowledge of nutritional science, counseling skills, and a nonjudgmental attitude can provide expertise in this area.